This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results

10/22/14 - 11:52 AM EDT

But you're getting way ahead of the facts if you think Regulus has a game-changing hepatitis C therapy in its grasp already. There's a lot more questions to be answered.

READ FULL POST

Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results

10/22/14 - 08:39 AM EDT

My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.

READ FULL POST

Some Potential Targets for Shire to Buy With $1.6B in Free Money

10/21/14 - 09:29 AM EDT

Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?

READ FULL POST

First Detailed Look at Celgene Crohn's Disease Pill Impresses

10/20/14 - 10:56 AM EDT

As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.

READ FULL POST

FDA Approves Competing Lung Disease Drugs From Roche and Boehringer

10/15/14 - 04:07 PM EDT

U.S. patients suffering from idiopathic pulmonary fibrosis finally gain access to Esbriet, approved for use in Europe since early 2011.

READ FULL POST

Gilead Sciences Falls Amid Worries Over Hep-C Drug Price

10/14/14 - 10:53 AM EDT

It's one thing for small-cap biotech stocks to trade horribly, but healthcare investors take notice when shares of Gilead Sciences GILD take a turn south.

READ FULL POST

Blame Arrowhead Management Entirely for Today's Epic Collapse

10/08/14 - 03:52 PM EDT

CEOs of early stage biotech companies like Arrowhead cannot deliver nasty surprises to Wall Street, yet some inexplicable reason, Anzalone totally botched the job.

READ FULL POST

The Disgusting Reaction to Ebola Patient's Death by Tekmira, Chimerix Traders

10/08/14 - 11:33 AM EDT

Tekmira shares surge after Thomas Duncan's death announced.

READ FULL POST

Arrowhead Research Sinks on Disappointing Hepatitis B Drug Data

10/08/14 - 10:38 AM EDT

In an ongoing phase II study, ARC-520 dosed at 2 mg/kg induced a 0.3 log reduction in HBsAG, a measure of the presence of hepatitis B virus in the body.

READ FULL POST

It's True, Small-Cap Biotech Stocks Are Acting Badly These Days

10/07/14 - 11:39 AM EDT

For the past three months, small-cap biotech stocks have been underperforming the broader market.

READ FULL POST

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs